{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=14", "query": { "intervention": "Monoclonal antibody - Dose Escalation", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 886, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T08:30:59.658Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Papillomavirus-Related Carcinoma", "Human Papillomavirus Positive Oropharyngeal Carcinoma", "Human Papillomavirus Positive Cervical Carcinoma", "Human Papillomavirus Positive Anal Carcinoma", "Human Papillomavirus Positive Vulvar Carcinoma", "Human Papillomavirus Positive Penile Carcinoma" ], "interventions": [ { "name": "HPV Specific T Cells", "type": "GENETIC" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "DRUG", "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2015-09", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02379520" }, { "nct_id": "NCT04150497", "title": "Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "UCART22", "type": "BIOLOGICAL" }, { "name": "CLLS52", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cellectis S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "15 Years to 50 Years" }, "enrollment_count": 52, "start_date": "2019-10-14", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 14, "location_summary": "Los Angeles, California • Aurora, Colorado • Denver, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150497" }, { "nct_id": "NCT00618696", "title": "Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-CD45 monoclonal antibody AHN-12", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 anti-CD45 monoclonal antibody AHN-12", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2005-07", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00618696" }, { "nct_id": "NCT00711191", "title": "A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasm" ], "interventions": [ { "name": "monoclonal antibody", "type": "BIOLOGICAL" }, { "name": "chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2008-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2013-12-24", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Philadelphia, Pennsylvania", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711191" }, { "nct_id": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2016-03-09", "completion_date": "2022-08-04", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 10, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Pembroke, Florida + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Pembroke", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611323" }, { "nct_id": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "INCA33890", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2024-01-04", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179160" }, { "nct_id": "NCT05216835", "title": "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Sabestomig (AZD7789)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "16 Years to 101 Years" }, "enrollment_count": 45, "start_date": "2022-03-18", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 5, "location_summary": "Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216835" }, { "nct_id": "NCT00631878", "title": "Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neonatal Staphylococcal Sepsis" ], "interventions": [ { "name": "Pagibaximab (formerly BSYX-A110)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biosynexus Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Days", "maximum_age": "7 Days", "sex": "ALL", "summary": "3 Days to 7 Days" }, "enrollment_count": 53, "start_date": "2001-11", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2008-03-10", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00631878" }, { "nct_id": "NCT01786135", "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Precursor B-cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "SGN-CD19A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 64, "start_date": "2013-02", "completion_date": "2017-02-16", "has_results": false, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786135" }, { "nct_id": "NCT00073749", "title": "Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "Inotuzumab ozogamicin [CMC-544]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 79, "start_date": "2003-08", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2018-12-17", "last_synced_at": "2026-10-14T08:30:59.658Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Chicago, Illinois • Buffalo, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073749" } ] }